NEW YORK (GenomeWeb News) – Biotech firm Biodesy said today that it has closed a $15 million Series A financing round with investments from 5AM Ventures, Pfizer Venture Investments, and Roche Venture Fund.

Additionally, the company announced that it has named Greg Yap as CEO and a director. Biodesy founder Joshua Salafsky has been appointed as chief science officer and a director.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."